pharmaceutical-investing MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
pharmaceutical-investing MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 in Alcohol Use Disorder and Withdrawal
pharmaceutical-investing Eloxx Pharmaceuticals Announces Uplisting to Nasdaq and Pricing of $50 Million Public Offering of Common Stock
pharmaceutical-investing MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre
MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
pharmaceutical-investing MediciNova Announces Closing of Underwritten Public Offering of Common Stock
CrowdStrike Named a Customers' Choice in the 2026 Gartner® Peer Insights 'Voice of the Customer' for Endpoint Protection Platforms Report
Aether Global Innovations Enters Exclusive Canadian Agency Agreement with Bravo Zulu Drone Defense Inc.